Cite
HARVARD Citation
Zhou, C. et al. (2020). Loss of AKR1C1 is a good prognostic factor in advanced NPC cases and increases chemosensitivity to cisplatin in NPC cells. Journal of cellular and molecular medicine. 24 (11), pp. 6438-6447. [Online].